Demand for tuberculous meningitis treatment will increase through 2036, with antibiotic therapy at 64.5% of the treatment segment in 2026. Hospitals lead the end-user segment with a 58.7% share. The market is projected to reach USD 184.4 billion in 2026 and USD 362.83 billion by 2036, creating an incremental opportunity of USD 178.38 billion.